Compare MAN & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAN | MNKD |
|---|---|---|
| Founded | 1948 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 1994 | 2004 |
| Metric | MAN | MNKD |
|---|---|---|
| Price | $33.72 | $4.24 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $35.67 | $8.69 |
| AVG Volume (30 Days) | 1.1M | ★ 4.8M |
| Earning Date | 04-16-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $17,957,100,000.00 | $348,966,000.00 |
| Revenue This Year | $5.12 | $35.81 |
| Revenue Next Year | $3.42 | $11.89 |
| P/E Ratio | $675.40 | ★ N/A |
| Revenue Growth | 0.58 | ★ 22.23 |
| 52 Week Low | $25.15 | $2.23 |
| 52 Week High | $47.34 | $6.51 |
| Indicator | MAN | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 53.65 | 69.60 |
| Support Level | $28.29 | $2.56 |
| Resistance Level | $36.87 | $4.29 |
| Average True Range (ATR) | 1.64 | 0.21 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 38.49 | 88.20 |
ManpowerGroup Inc provides workforce solutions and services, including recruitment and assessment, upskilling, reskilling, training and development, career management, outsourcing, and workforce consulting. The company leverages its trusted brands, industry knowledge, and AI-enabled assessments and offers an extensive portfolio of training and leadership development solutions. Its reportable segments are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others, with Staffing and Interim generating the majority of revenue. It operates in the Americas, Southern Europe, Northern Europe, and APME. The company derives the maximum geographical revenue from the Southern European region.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.